Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ryan J. Caddell"'
Autor:
Ryan J. Caddell, Brian C. Betts, Jun-Min Zhou, Janelle Perkins, Farhad Khimani, Taiga Nishihori, Asmita Mishra, Joseph Pidala, Elizabeth DiMaggio, Claudio Anasetti, Lia Perez, Hugo F. Fernandez, Rebecca Tombleson
Publikováno v:
Leukemialymphoma. 61(7)
Optimal conditioning chemotherapy for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) remains uncertain. Myeloablative regimens such as fludarabine/busulfan are favored over reduced-intensity fludarabine/melphalan (Flu/M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc290b9dece0c6b1f98fd8e470ecb639
https://pubmed.ncbi.nlm.nih.gov/32476524
https://pubmed.ncbi.nlm.nih.gov/32476524
Publikováno v:
Blood. 136:3-4
Introduction High-risk subtypes of DLBCL, including high-grade B-cell lymphomas (HGBCL) with rearrangements of c-MYC (MYC-R), BCL2 and/or BCL6 [or double hit and triple hit lymphomas (DHL/THL)], double expressor lymphoma (DEL), and patients with Inte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0827428079eac47f76929569a54c6342
https://doi.org/10.1182/blood-2020-140085
https://doi.org/10.1182/blood-2020-140085
Autor:
Leidy Isenalumhe, Javier Pinilla Ibarz, Julio C. Chavez, Rebecca A. Nelson, Ryan J. Caddell, Bijal D. Shah, Hayder Saeed, Celeste M. Bello, Lubomir Sokol
Publikováno v:
Blood. 134:5292-5292
Background: Asparaginase may improve outcomes in chemotherapy resistant malignancy, especially of lymphoid origin. L-asparaginase (L-ASP) was introduced in 1992 and hence has been incorporated in multiple regimens. An effective regimen including ster
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::897693a382f3cf3b6678ed09969cd181
https://doi.org/10.1182/blood-2019-128435
https://doi.org/10.1182/blood-2019-128435
Autor:
Ryan J. Caddell, Rami S. Komrokji, Katherine Tobon, Hugo F. Fernandez, David A. Sallman, Kendra Sweet, Chetasi Talati, Eric Padron, Alan F. List, Jeffrey E. Lancet, Andrew T. Kuykendall
Publikováno v:
Blood. 134:2636-2636
Background: Patients with favorable risk acute myeloid leukemia (AML) by European LeukemiaNet (ELN) criteria are treated with intensive chemotherapy that yields high remission rates and is often curative. Intensive chemotherapy typically includes cyt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5758d11eb8bca17bbda46b6fb1e4209f
https://doi.org/10.1182/blood-2019-129166
https://doi.org/10.1182/blood-2019-129166
Autor:
Eunice S. Wang, Maria R. Baer, Vu H. Duong, Kebede H. Begna, Zeba N. Singh, Danielle Shafer, Kendra Sweet, Aref Al-Kali, Ryan J. Caddell
Publikováno v:
Blood. 132:2658-2658
Background: Acute leukemias of ambiguous lineage (ALAL), including acute undifferentiated leukemia and mixed phenotype acute leukemia (MPAL), are rare hematologic malignancies, accounting for only 2-5% of cases of acute leukemia. Outcomes are general
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d8707986a6b117035746925aa744864c
https://doi.org/10.1182/blood-2018-99-115448
https://doi.org/10.1182/blood-2018-99-115448
Autor:
Joseph Pidala, Ernesto Ayala, Zhenjun Ma, Rebecca Tombleson, Brian C. Betts, Taiga Nishihori, Frederick L. Locke, Ryan J. Caddell, Braydon Schaible, Claudio Anasetti, Elizabeth DiMaggio, Hugo F. Fernandez, Asmita Mishra, Mohamed A. Kharfan-Dabaja
Publikováno v:
Blood. 128:3486-3486
Introduction: Fludarabine (Flu)-based conditioning regimens, combined with either melphalan (Mel) or intravenous busulfan (Bu), are often utilized in patients undergoing allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10c7af7a86a9a53d7dda4ac0c4bb68e6
https://doi.org/10.1182/blood.v128.22.3486.3486
https://doi.org/10.1182/blood.v128.22.3486.3486